Rel/NF-κB and IκB factors in oncogenesis

Seminars in Cancer Biology

Volumn 8, Issue 2, 1997, Pages 103-111

  Luque, Ignacio ^a   Gélinas, Céline ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

I B; NF B; Oncogenesis; Rel; Transcription factor

Indexed keywords

DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; REGULATOR PROTEIN; TRANSCRIPTION FACTOR;

BIRD; BREAST CARCINOMA; CANCER; CARCINOGENESIS; CARCINOGENICITY; CELL GROWTH; CELL TRANSFORMATION; CHROMOSOME 2P; COLON CARCINOMA; DNA BINDING; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; HUMAN; IMMUNE SYSTEM; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAMMAL; MULTIGENE FAMILY; NONHUMAN; ONCOGENE; PROTEIN SECRETION; RETROVIRUS; REVIEW; TUMOR CELL;

EID: 0031126792     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1997.0061     Document Type: Article

References (103)

1. 1. Baeuerle PA, Henkel T (1994) Function and activity of NF-κB in the immune system. Annu Rev Immunol 12:141-179
2. 2. Gilmore TD, Koedood M, Piffat KA, White DW (1996) Rel/ NF-κB/ IκB proteins and cancer. Oncogene 13:1367-1378
3. 3. Houldsworth J, Mathew S, Rao PH, Dyomina K, Louie DC, Parsa N, Offit K, Chaganti RSK (1996) REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 87:25-29
4. 4. Barth CF, Ewert DL, Olson WC, Humphries EH (1990) Reticuloendotheliosis virus REV-T(REV-A)-induced neoplasia: development of tumors within the T-lymphoid and myeloid lineages. J Virol 64:6054-6062
5. 5. Boehmelt G, Madruga J, Dorfler P, Briegel K, Schwartz H, Enrietto PJ, Zenke M (1995) Dendritic cell progenitor is transformed by a conditional v-Rel estrogen receptor fusion protein v-RelER. Cell 80:341-352
6. 6. Beug H, Muller H, Doederlein G, Graf T (1981) Hematopoietic cells transformed in vitro by REV-T avian reticuloendotheliosis virus express characteristics of very immature lymphoid cells. Virology 115:295-309
7. 7. Moore BE, Bose HR Jr (1988) Expression of the v-rel oncogene in reticuloendotheliosis virus-transformed fibroblasts. Virology 162:377-387
8. 8. Morrison LE, Boehmelt G, Enrietto PJ (1992) Mutations in the rel-homology domain alter the biochemical properties of v-re\ and render it transformation defective in chicken fibroblasts. Oncogene 7:1137-1147
9. 9. Gélinas C, Temin HM (1988) The v-rel oncogene encodes a cell-specific trancriptional activator of certain promoters. Oncogene 3:349-355
10. 10. Hannink M, Temin HM (1989) Transactivation of gene expression by nuclear and cytoplasmic rel proteins. Mol Cell Biol 9:4323-4336
11. 11. Schwartz RC, Witte ON (1988) A recombinant murine retrovirus expressing v-rel is cytopathic. Virology 165:182-190
12. 12. Carrasco D, Risso CA, Dorfman K, Bravo R (1996) The v-rel oncogene promotes malignant T-cell leukemia/ lymphoma in transgenic mice. EMBO J 15:3640-3650
13. 13. Bose HR Jr (1992) The Rel family: models for transcriptional regulation and oncogenic transformation. Biochim Biophys Acta 1114:1-17
14. 14. Hrdlicková R, Nehyba J, Humphries EH (1994) In vivo evolution of c-rel oncogenic potential. J Virol 68:2371-2382
15. 15. Bhat G, Temin HM (1990) Mutational analysis of v-rel, the oncogene of reticuloendotheliosis virus strain T. Oncogene 5:625-634
16. 16. Nehyba J, Hrdlicková R, Bose HR Jr (1997) Differences in κB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein. Oncogene 14:2881-2897
17. 17. Kamens J, Richardson P, Mosialos G, Brent R, Gilmore T (1990) Oncogenic transformation by v-Rel requires an amino-terminal activation domain. Mol Cell Biol 10:2840-2847
18. c-rel is a cytoplasmic protein in chicken embryo fibroblasts. Oncogene 5:257-265
19. 19. Richardson PM, Gilmore TD (1991) vRel is an inactive member of the Rel family of transcriptional activating proteins. J Virol 65:3122-3130
20. IκB-β inhibition of DNA binding by rel proteins. Mol Cell Biol 13:1769-1778
21. 21. Kralova J, Schatzle JD, Bargmann W, Bose HR Jr (1994) Transformation of avian fibroblasts overexpressing the c-rel proto-oncogene and a variant of c-rel lacking 40 C-terminal amino acids. J Virol 68:2073-2083
22. 22. Ishikawa H, Asano M, Kanda T, Kumar S, Gélinas C, Ito Y (1993) Two novel functions associated with the Rel oncoproteins: DNA replication and cell-specific transcriptional activation. Oncogene 8:2889-2896
23. 23. Walker WH, Stein B, Ganchi PA, Hoffman JA, Kaufman PA, Ballard DW, Hannink M, Greene WC (1992) The v-rel oncogene: insights into the mechanism of transcriptional activation, repression and transformation. J Virol 66:5018-5029
24. 24. Smardova J, Walker A, Morrison LE, Kabrun N, Enrietto PJ (1995) The role of the carboxy terminus of v-Rel in transformation and activation of endogenous gene expression. Oncogene 10:2017-2026
25. 25. Xu X, Prorock C, Ishikawa H, Maldonado E, Ito X Gélinas C (1993) Functional interaction of the v-Rel and c-Rel oncoproteins with the TATA-binding protein and association with transcription factor IIB. Mol Cell Biol 13:6733-6741
26. 26. Sarkar S, Gilmore TD (1993) Transformation by the v-Rel oncoprotein requires sequences carboxy-terminal to the Rel homology domain. Oncogene 8:2245-2452
27. v-rel complexes. J Virol 64:584-591
28. 28. Gilmore TD, Temin HM (1986) Different localization of the product of the v-rel oncogene in chicken fibroblasts and spleen cells correlates with transformation by Rev-T. Cell 44:791-800
29. 29. Simek SL, Stephens RM, Rice NR (1986) Localization of the v-Rel protein in reticuloendotheliosis virus strain T-transformed lymphoid cells. J Virol 59:120-126
30. 30. Gilmore TD, Temin HM (1988) v-rel oncoproteins in the nucleus and in the cytoplasm transform chicken spleen cells. J Virol 62:703-714
31. 31. Rottjakob EM, Sachdev S, Leanna CA, McKinseyTA, Hannink M (1996) PEST-dependent cytoplasmic retention of v-Rel by IκBα: evidence that IκBκ regulates cellular localization of c-Rel and v-Rel by distinct mechanisms. J Virol 70:3176-3188
32. 32. Sachdev S, Diehl JA, McKinsey TA, Hans A, Hannink M (1997) A threshold nuclear level of the v-Rel oncoprotein is required for transformation of avian lymphocytes. Oncogene 14:2585-2594
33. 33. Boehmelt G, Walker A, Kabrun N, Mellitzer G, Beug H, Zenke M, Enrietto PJ (1992) Hormone-regulated v-rel estrogen receptor fusion protein: reversible induction of cell transformation and cellular gene expression. EMBO J 11:4641-4652
34. 34. Capobianco AJ, Gilmore TD (1993) A conditional mutant of v-Rel containing sequences from the human estrogen receptor. Virology 193:160-170
35. 35. White DW, Gilmore TD (1993) Temperature-sensitive transforming mutants of the v-rel oncogene. J Virol 67:6876-6881
36. 36. Zong W-X, Farrell M, Bash J, Gélinas C (1997) v-Rel prevents apoptosis in transformed lymphoid cells and blocks TNFα-induced cell death. Oncogene 14:in press
37. 37. White DW, Pitoc GA, Gilmore TD (1996) Interaction of the v-Rel oncoprotein with NF-κB and IκB proteins: heterodimers of a transformation-defective v-Rel mutant and NF-κB p52 are functional in vitro and in vivo. Mol Cell Biol 16:1169-1178
38. 38. Perez P, Lira SA, Bravo R (1995) Overexpression of RelA in transgenic mouse thymocytes: Specific increase in levels of the inhibitor protein IκBα. Mol Cell Biol 15:3523-3530
39. 39. Weih F, Lira SA, Bravo R (1995) Overexpression of RelB in transgenic mice does not affect IκBα levels: differential regulation of RelA and RelB by the inhibitor protein. Oncogene 12:445-449
40. 40. Zhang G, Slaughter C, Humphries E (1995) v-rel induces ectopic expression of an adhesion molecule, DM-GRASP, during B-lymphoma development. Mol Cell Biol 15:1806-1816
41. 41. Neiman PE, Thomas SJ, Loring G (1991) Induction of apoptosis during normal and neoplastic B-cell development in the bursa of Fabricius. Proc Natl Acad Sci USA 88:5857-5861
42. 42. White DW, Roy A, Gilmore TD (1995) The v-Rel oncoprotein blocks apoptosis and proteolysis of IκB-α in transformed chicken spleen cells. Oncogene 10:857-868
43. 43. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ (1997) Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science 275:523-527
44. 44. Sif S, Gilmore TD (1994) Interaction of the v-Rel oncoprotein with the cellular transcription factor Sp1. J Virol 68:7131-7138
45. 45. Diehl JA, Hannink M (1994) Identification of a C/ EBP-Rel complex in avian lymphoid cells. Mol Cell Biol 14:6635-6646
46. 46. Kontgen F, Grumont RJ, Strasser A, Metcaff D, Li R, Tarlinton D, Gerondakis S (1995) Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev 9:1965-1977
47. 47. Huguet C, Bouali F, Enrietto PJ, Stehelin D, Vandenbunder B, Abbadie C (1997) The avian transcription factor c-Rel is expressed in lymphocyte precursor cells and antigen-presenting cells during thymus development. Dev Immunol: in press
48. 48. Abbadie C, Kabrun N, Bouali F, Smardova J, Stéhelin D, Vandenbunder B, Enrietto PJ (1993) High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro. Cell 75:899-912
49. 49. Nehyba J, Hrdlicková R, Humphries EH (1994) Evolution of the oncogenic potential of v-rel: rel-induced expression of immunoregulatory receptors correlates with tumor development and in vitro transformation. J Virol 68:2039-2050
50. 50. Bash J, Zong W-X, Gélinas C (1997) c-Rel arrests cell proliferation and affects critical regulators of the G1/ S phase transition. Submitted
51. 51. Huguet C, Mattot V, Bouali E, Stéhelin D, Vandenbunder B, Abbadie C (1997) The avian transcription factor c-Rel is induced and translocates into the nucleus of thymocytes undergoing apoptosis. Cell Death Diff 4:413-422
52. 52. Mathew S, Murty VVVS, Dalla-Favera R, Chaganti RSK (1993) Chromosomal localization of genes encoding the transcription factors c-rel, NF-κBp50, NF-κBp65 and lyt-10 by fluorescence in situ hybridization. Oncogene 8:191-193
53. 53. Brownell E, Fell HP, Tucker PW, Geuzts AHM, Magemeijer A, Rice NR (1988) Regional localization of the human c-rel locus using translocation chromosome analysis. Oncogene 2:527-529
54. 54. Lu D, Thompson JD, Gorski GK, Rice NR, Mayer MG, Yanis JJ (1991) Alterations at the rel locus in human lymphoma. Oncogene 6:1235-1241
55. 55. Joos S, Otano-Joos MI, Ziegler S, Brüderlein S, du Manoir S, Bentz M, Möller P, Lichter P (1996) Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87:1571-1578
56. 56. Kabrun N, Bumstead N, Hayman MJ, Enrietto PJ (1990) Characterization of a novel promoter insertion in the c-rel locus. Mol Cell Biol 10:4788-4794
57. 57. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G (1989) bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. New Engl J Med 320:1047-1054
58. 58. Mukhopadhyay T, Roth JA, Maxwell SA (1995) Altered expression of the p50 subunit of the NF-κB transcription factor complex in non-small cell lung carcinoma. Oncogene 11:999-1003
59. 59. Neri A, Chang CC, Lombardi L, Salina M, Corradini P, Maiolo AT, Chaganti RSK, Dalla-Favera R (1991) B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50. Cell 67:1075-1087
60. 60. Fracchiolla NS, Lombardi L, Salina M, Migliazza A, Baldini L, Berti E, Cro L, Polli E, Maiolo A, Neri A (1993) Structural alterations of the NF-κB transcription factor lyt-10 in lymphoid malignancies. Oncogene 8:2839-2845
61. 61. Thakur S, Lin HC, Tseng WT, Kumar S, Bravo R, Foss F, Gélinas C, Rabson AB (1994) Rearrangement and altered expression of the NF-κB2 gene in human cutaneous T-lymphoma cells. Oncogene 9:2335-2344
62. 62. Neri A, Fracchiolla NS, Roscetti E, Garatti S, Trecca D, Boletini A, Perletti L, Baldini L, Maiola AT, Berti E (1995) Molecular analysis of cutaneous B- and T-cell lymphomas. Blood 86:3160-3172
63. 63. Migliazza A, Lombardi L, Rocchi M, Trecca D, Chang CC, Antonacci R, Fracchiolla NS, Ciana P, Maiolo AT, Neri A (1994) Heterogeneous chromosomal aberrations generate 3′ truncations of the NF-κB2/ lyt-10 gene in lymphoid malignancies. Blood 84:3850-3860
64. 64. Zhang J, Chang CC, Lombardi L, Dalla-Favera R (1994) Rearranged NF-κB2 gene in HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional represser functions. Oncogene 10:1931-1937
65. 65. Chang C-C, Zhang J, Lombardi L, Neri A, Dalla-Favera R (1995) Rearranged NF-κB2 genes in lymphoid neoplasms code for constitutiveIy active nuclear transactivators. Mol Cell Biol 15:5180-5187
66. 66. Bours V, Burd PR, Brown K, Villalobos J, Park S, Ryseck R-P, Bravo R, Kelly K, Siebenlist U (1992) A novel mitogen-inducible gene product related to p50/ p105-NF-κB participates in transactivation through a κB site. Mol Cell Biol 12:685-695
67. 67. Chang C-C, Zhang J, Lombardi L, Neri A, Dalla-Favera R (1994) Mechanism of expression and role in transcriptional control of the proto-oncogene NF-κB2/ LYT-10. Oncogene 9:923-933
68. 68. Ciana P, Neri A, Cappellini C, Cavallo F, Pomati M, Chang C-C, Maiolo AT, Lombardi L (1997) Constitutive expression of lymphoma-associated NF-κB2/ Lyt-10 proteins is tumorigenic in murine fibroblasts. Oncogene 14:1805-1810
69. 69. Bours V, Dejardin E, Goujon-Letawe F, Merville M-P, Castronovo V (1994) The NF-κB transcription factor and cancer: high expression of NF-κB- and IκB-related proteins in tumor cell lines. Biochem Pharmacol 47:145-149
70. 70. Dejardin E, Bourizzi G, Bellahcene A, Castronovo V, Merville M-P, Bours V (1995) Highly expressed p100/ p52 (NF-κB2) sequesters other NF-κB-related proteins in the cytoplasm of human breast cancer cells. Oncogene 11:1835-1841
71. 71. Dejardin E, Deregowski V, Greimers R, Merville M-P, Bours V (1997) Regulation of MHC class I expression byNF-κB-related proteins in breast cancer cells. Submitted
72. 72. Liptay S, Schmid RM, Perkins ND, Meltzer P, Altherr MR, McPherson JD, Wasmuth JJ, Nabel GJ (1992) Related subunits of NF-κB map to two distinct loci associated with translations in leukemia, NF-κBl and NF-κB2. Genomics 13:287-292
73. 73. Trecca D, Guerrini L, Fracchiolla NS, Pomati M, Baldini L, Maiolo AT, Neri A (1997) Identification of a tumor-associated mutant form of the NF-κB RelA gene with reduced DNA-binding and transactivating activities. Oncogene 14:791-799
74. 74. Lai JL, Zandeck M, Mary JY Bernandi E, Izydorczyk V, Flatchif M, Morel P, Jovet JP, Bautos F, Facon T (1995) Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 85:2490-2497
75. 75. Van den Berghe H, Parloir C, David G, Michaux JL, Sokal G (1979) A new characteristic karyotypic anomaly in lymphoproliferative disorders. Cancer 44:188-195
76. 76. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D (1995) Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 376:167-170
77. 77. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, Royer H-D, Scheidereit C, Dörken B (1996) High-level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/ Reed-Sternberg cells. Blood 87:4340-4347
78. 78. Kitajima I, Shinohara T, Bilakovics J, Brown DA, Xu X, Nerenberg M (1992) Ablation of transplanted HTLV-1 Tax-transformed tumors in mice by antisense inhibition of NF-κB. Science 258:1792-1795
79. 79. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA, Narayanan R (1993) Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci USA 90:9901-9905
80. 80. Motokura T, Arnold A (1993) PRAD1/ cyclin D1 proto-oncogene: genomic organization, 5′ DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. Genes Chrom Cane 7:89-95
81. 81. Narayanan R, Klement JF, Ruben SM, Higgins KA, Rosen CA (1992) Identification of a naturally occurring transforming variant of the p65 subunit of NF-κB. Science 256:367-370
82. 82. Grimm S, Baeuerle PA (1994) Failure of the splicing variant p65δ of the NF-κB subunit p65 to transform fibroblasts. Oncogene 9:2391-2398
83. 83. Maxwell SA, Mukhopadhyay T (1995) A novel NF-κB p65 spliced transcript lacking exons 6 and 7 in a non-small cell lung carcinoma cell line. Gene 166:339-340
84. 84. Ohno H, Takimoto G, McKeithan TW (1990) The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 60:991-997
85. 85. Michaux L, Mecucci C, Stul M, Wlodarska I, Hernandez JM, Meeus P, Michaux JL, Scheiff MM, Noel H, Louwagie A, Criel A, Boogaerts M, Van Orshoven A, Cassiman JJ, Van Den Berghe H (1996) BCL3 rearrangement and t(14;19)(q32;q13) in lymphoproliferative disorders. Genes Chrom Cane 15:38-47
86. 86. Schwarz EM, Krimpenfort P, Berns A, Verma IM (1997) Immunological defects in mice with a targeted disruption in Bcl-3. Genes Dev 11:187-197
87. 87. Franzoso G, Carlson L, Scharton-Kersten T, Shores EW, Epstein S, Grinberg A, Tran T, Shacter E, Leonardi A, Anver M, Love P, Sher A, Siebenlist U (1997) Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture and germinal center reactions. Immunity 6:479-490
88. 88. Lenardo M, Siebenlist U (1994) Bcl-3-mediated nuclear regulation of the NF-κB transactivating factor. Immunol Today 15:145-147
89. 89. Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U (1993) The oncoprotein Bcl-3 directly trans-activates through κB motifs via association with DNA-binding p50B homodimers. Cell 72:729-739
90. 90. Caamaño JH, Perez P, Lira S, Bravo R (1996) Constitutive expression of Bcl-3 in thymocytes increases the DNA binding of NF-κB1 (p50) homodimers in vivo. Mol Cell Biol 16:1342-1348
91. 91. Beauparlant P, Kwan I, Bitar R, Chou P, Koromilas AE, Sonenberg N, Hiscott J (1994) Disruption of IκBα regulation by antisense RNA expression leads to malignant transformation. Oncogene 9:3189-3197
92. 92. Beg AA, Sha WC, Bronson RT, Baltimore D (1995) Constitutive NF-κB activation, enhanced granulopoiesis, and neonatal lethality in IκBα-deficient mice. Genes Dev 9:2736-2746
93. 93. Klement JF, Rice NR, Car BD, Abbondanzo SJ, Powers GD, Bhatt H, Chen C-H, Rosen CA, Stewart CL (1996) IκBα deficiency results in a sustained NF-κB response and severe widespread dermatitis in mice. Mol Cell Biol 16:2341-2349
94. 94. Jung M, Zhang Y, Lee S, Dritschilo A (1995) Correction of radiation sensitivity in ataxia telangiectasia cells by a truncated IκBα. Science 268:1619-1621
95. 95. Jung M, Kondratyev A, Lee SA, Dimtchev A, Dritschilo A (1997) ATM gene product phosphorylates IκB-α. Cancer Res 57:24-27
96. 96. Lee H, Arsura M, Wu M, Duyao M, Buckler AJ, Sonenshein GE (1995) Role of Rel-related factors in control of c-myc gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line. J Exp Med 181:1169-1177
97. 97. Liu Z, Hsu H, Goeddel DV, Karin M (1996) Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 87:565-575
98. 98. Beg AA, Baltimore D (1996) An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274:782-784
99. 99. Wang C-Y, Mayo MW, Baldwin AS Jr (1996) TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274:784-787
100. 100. Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D, FitzGerald MJ, Rothstein TL, Sherr DH, Sonenshein GE (1996) Inhibition of NF-κB/ Rel induces apoptosis of murine B cells. EMBO J 15:4682-4690
101. 101. Arsura M, Wu M, Sonenshein G (1996) TGFβ1 inhibits NF-κB/ Rel activity inducing apoptosis of B cells: transcriptional activation of IκBα. Immunity 5:31-40
102. 102. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM (1996) Suppression of TNF-α-induced apoptosis by NF-κB. Science 274:787-789
103. 103. Grimm S, Bauer MKA, Baeuerle PA, Schulze-Osthoff K (1996) Bcl-2 down-regulates the activity of transcription factor NF-κB induced upon apoptosis. J Cell Biol 134:13-23